Senores Pharmaceuticals IPO Day 2 Live Updates: Key Highlights, Subscription Status, and Insights
Founded in 2017, Senores Pharmaceuticals specialises in the development and manufacturing of a wide range of pharmaceutical products certified by global food and drugs authorities.
The initial public offering (IPO) of Senores Pharmaceuticals opened on December 20, 2024, and will close on December 24, 2024.
Senores Pharmaceuticals IPO Details
- The company aims to raise 582.11 crore through its IPO with a fresh issue of 500 crore and 82.11 crore for Offer for Sale (OFS).
- The issue opened on December 20, 2024, and is scheduled to close on December 24, 2024.
- The price band is set between ₹372 to ₹391 per share.
- Shares for Senores Pharmaceuticals IPO will be allotted by December 26, 2024.
- Senores Pharmaceuticals IPO listing date for NSE and BSE is December 30, 2024.
- The minimum lot size for retail investors is 38 shares, requiring an investment of ₹14,858. For small non-institutional investors, the minimum investment is 14 lots (532 shares), totalling ₹2,08,012. For large non-institutional investors, the minimum investment is 68 lots (2,584 shares), amounting to ₹10,10,344.
- Book-running lead managers for Senores Pharmaceuticals IPO are Equirus Capital Private Limited, Ambit Private Limited, and Nuvama Wealth Management Limited.
- Link Intime India Private Ltd is the registrar to the IPO.
Use of Proceeds
- To finance capex for establishing a sterile injection manufacturing facility in Atlanta for subsidiary Havix Group, Inc., operating as Aavis Pharmaceuticals.
- To repay or pre-pay certain company borrowings.
- To meet its working capital requirements.
- To support the working capital needs of subsidiaries Senores Pharmaceuticals Inc. (SPI) and Ratnatris Pharmaceutical Private Limited.
- For acquisitions, general corporate purposes, and other strategic growth initiatives.
- Repay or pre-pay borrowings taken by the subsidiary Havix.
Senores Pharmaceuticals IPO Day 2 Subscription Status
December 23, 2024, 3:39:19 PM (Day 2).
On Day 2, Senores Pharmaceuticals IPO was subscribed 11.9 times, with Retail Investors subscribing 32.04 times, Non-Institutional Buyers 21.32 times, and Qualified Institutional Buyers showing the least interest with 0.36 times.
Senores Pharmaceuticals IPO Day 1 Subscription Status
On Day 1, the Senores Pharmaceuticals IPO was subscribed 1.94 times. The Retail Investors portion saw 7.9x subscription, Non-Institutional Buyers 1.77x, and the Qualified Institutional buyers segment was 0.01x.
Senores Pharmaceuticals Business Overview
Senores Pharmaceuticals is a research-driven pharmaceutical company, serving 49 countries across five continents with a diverse range of pharmaceutical products. The company's product line includes a variety of tablets and capsules across key therapeutic areas, including antibiotics and anti-fungal treatments.
Senores Pharmaceuticals Financial Highlights
- As of 31st March 2024, the company recorded revenue from operations of Rs 214.52 crore, up 507% from Rs 35.34 crore in the previous year.
- Senores Pharmaceuticals profit after tax (PAT) for FY24 stood at Rs 32.71 crore compared to Rs 8.43 crore in the previous year. This is a rise of 288%.
Key Ratios
|
Year |
FY24 |
|
ROE |
23.60% |
|
ROCE |
11.73% |
|
EBITDA Margin |
20.70% |
|
PAT Margin |
15.25% |
|
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory. To read the RA disclaimer, please click here |